Sana Biotechnology (NASDAQ:SANA) Shares Up 7.6% – Time to Buy?

Posted by Geri Gentry on Jun 17th, 2026

Sana Biotechnology, Inc. (NASDAQ:SANA – Get Free Report)’s share price was up 7.6% during mid-day trading on Wednesday . The stock traded as high as $3.00 and last traded at $3.0450. Approximately 943,897 shares were traded during trading, a decline of 70% from the average daily volume of 3,132,178 shares. The stock had previously closed at $2.83.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on SANA shares. Rodman & Renshaw started coverage on shares of Sana Biotechnology in a research report on Monday, May 11th. They set a “buy” rating and a $16.00 price objective for the company. Weiss Ratings cut shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Zacks Research cut shares of Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. HC Wainwright decreased their price objective on shares of Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, March 4th. Finally, Wedbush lifted their price objective on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 14th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Sana Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

View Our Latest Research Report on Sana Biotechnology

Sana Biotechnology Trading Up 12.5%

The company’s 50 day moving average is $3.20 and its 200 day moving average is $3.78. The stock has a market capitalization of $885.80 million, a price-to-earnings ratio of -3.41 and a beta of 2.14.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01. Analysts anticipate that Sana Biotechnology, Inc. will post -0.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Sana Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of SANA. Royal Bank of Canada raised its stake in Sana Biotechnology by 76.8% during the 1st quarter. Royal Bank of Canada now owns 12,285 shares of the company’s stock worth $35,000 after acquiring an additional 5,338 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in Sana Biotechnology during the 3rd quarter worth $36,000. Rockefeller Capital Management L.P. increased its stake in Sana Biotechnology by 74.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock valued at $39,000 after purchasing an additional 4,088 shares during the period. Russell Investments Group Ltd. acquired a new position in Sana Biotechnology in the third quarter valued at $39,000. Finally, LRI Investments LLC acquired a new position in Sana Biotechnology in the fourth quarter valued at $41,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

About Sana Biotechnology

(Get Free Report)

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.